URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>
Archive for the ‘Bone loss’ Category
Prostate cancer patients at risk of losing bone mineral content
Posted in Bone loss, tagged BETTER HEALTH RESEARCH, bone mineral content, cancer research, catheter, prostablog, prostate blog, PROSTATE CANCER on July 18, 2010| Leave a Comment »
BETTER HEALTH RESEARCH: Prostate cancer patients may be at an increased risk of suffering from bone mineral content loss compared to men who are cancer-free. READ MORE>
$1100-per-dose bone fracture preventing drug gets FDA approval
Posted in Bone loss, PROSTATE CANCER, tagged advanced cancer patients, advanced prostate cancer, Amgen Inc., catheter, Denosumab, fractures, osteoporosis drug, Prolia, prostablog, prostate, PROSTATE CANCER, prostate cancer treatments, prostate treatment, REUTERS, U.S. Food and Drug Administration on June 12, 2010| Leave a Comment »
REUTERS: The US Food and Drug Administration has approved the sale of Amgen Inc’s osteoporosis drug Prolia – denosumab – to help prevent fractures in advanced cancer patients just days after the medicine received European approval. It will cost $US825 per 60 milligram injection. READ MORE>
Radiotherapy prostate patients face risk of hip fracture
Posted in Bone loss, PROSTATE CANCER, Radiotherapy, tagged bone health, external beam radiation therapy, hip fracture, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate treatment, Radiotherapy on June 3, 2010| Leave a Comment »
URO TODAY: Patients undergoing three dimensional external beam radiation therapy for prostate cancer may be at an increased risk of hip fracture and could benefit from additional measures to improve bone health following treatment. READ MORE>
Study shows generic drug prevents bone loss in prostate cancer patients
Posted in Bone loss, Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, tagged (Actonel), bisphosphonate risedronate, Bone loss, cancer research, catheter, generically available, hormonal therapy, Mike Scott, New Prostate Cancer Info-link, oral, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments on May 26, 2010| Leave a Comment »
NEW PROSTATE CANCER INFO-LINK: A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. READ MORE>
Fracture-reducing drug for prostate cancer patients also cuts down hormone therapy hot flushes
Posted in Bone loss, Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, androgen-deprivation therapy, cancer research, fracture-reducing drug, Hormone therapy, hot flashes, hot flushes, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, quality of life, toremifene, URO TODAY on October 18, 2009| Leave a Comment »
URO TODAY: A fracture-reducing drug called toremifene has a useful side effect when used on prostate cancer patients – it significantly reduces hot flushes caused by hormone therapy. READ MORE>
False balls that release bone-loss drugs may make testicle removal viable option again
Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, androgen-deprivation therapy, Bone loss, cancer research, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, slow-release drugs, testes removal, testicular prostheses, testosterone control, URO TODAY on September 15, 2009| Leave a Comment »
URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>
Bayer and Norwegian company go ahead with new drug to treat bone loss in prostate cancer patients
Posted in Bone loss, PROSTATE CANCER, Treatment news, tagged advanced prostate cancer, Alpharadin, Bayer, Bone loss, hormone-refractory prostate cancer, NORWAY POST, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment on September 6, 2009| Leave a Comment »
NORWAY POST: Alpharadin, a new drug that treats men with hormone-refractory prostate cancer that has spread to the bone, will be developed by a Norwegian cancer therapeutics company and global drugs giant Bayer. READ MORE>
